MCID: MLG053
MIFTS: 16

Malignant Ovarian Brenner Tumor

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Malignant Ovarian Brenner Tumor

MalaCards integrated aliases for Malignant Ovarian Brenner Tumor:

Name: Malignant Ovarian Brenner Tumor 12 14
Malignant Brenner Tumor 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4217
MeSH 42 D001948
NCIt 47 C4270
SNOMED-CT 64 42194009
UMLS 69 C0334495

Summaries for Malignant Ovarian Brenner Tumor

Disease Ontology : 12 A malignant ovarian surface epithelial-stromal neoplasm that has material basis in the surface epithelium of the ovary.

MalaCards based summary : Malignant Ovarian Brenner Tumor, also known as malignant brenner tumor, is related to ovarian brenner tumor. An important gene associated with Malignant Ovarian Brenner Tumor is SMUG1 (Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1). The drugs Bevacizumab and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and brain.

Related Diseases for Malignant Ovarian Brenner Tumor

Diseases in the Ovarian Brenner Tumor family:

Malignant Ovarian Brenner Tumor

Diseases related to Malignant Ovarian Brenner Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 ovarian brenner tumor 10.0

Symptoms & Phenotypes for Malignant Ovarian Brenner Tumor

Drugs & Therapeutics for Malignant Ovarian Brenner Tumor

Drugs for Malignant Ovarian Brenner Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
5 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
6 Angiogenesis Inhibitors Phase 3
7 Angiogenesis Modulating Agents Phase 3
8 Antibodies Phase 3,Phase 1
9 Antibodies, Monoclonal Phase 3,Phase 1
10 Antimitotic Agents Phase 3,Phase 1
11 Antineoplastic Agents, Phytogenic Phase 3,Phase 1
12 Endothelial Growth Factors Phase 3
13 Immunoglobulins Phase 3,Phase 1
14 Mitogens Phase 3
15 Carotenoids Phase 3
16 Micronutrients Phase 3
17 Trace Elements Phase 3
18
Metformin Approved Phase 2 657-24-9 14219 4091
19
Iodine Investigational Phase 1, Phase 2 7553-56-2 807
20
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
21 Imatinib Mesylate Phase 2 123596
22 Protein Kinase Inhibitors Phase 2
23 Hypoglycemic Agents Phase 2
24
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
25
Glutamic Acid Approved, Nutraceutical Phase 1 56-86-0 33032
26
Doxil Approved June 1999 Phase 1 31703
27 Anti-Bacterial Agents Phase 1
28 Antibiotics, Antitubercular Phase 1
29 Topoisomerase Inhibitors Phase 1
30 Immunotoxins Phase 1
31
Formaldehyde Approved, Vet_approved 50-00-0 712
32 CHI3L1 protein, human

Interventional clinical trials:

(show all 16)

id Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
3 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
4 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
5 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
6 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
7 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
8 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
9 Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 paclitaxel;carboplatin;docetaxel;metformin hydrochloride;placebo
10 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
11 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
12 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
13 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
14 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
15 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Active, not recruiting NCT00899093
16 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Active, not recruiting NCT01080521

Search NIH Clinical Center for Malignant Ovarian Brenner Tumor

Genetic Tests for Malignant Ovarian Brenner Tumor

Anatomical Context for Malignant Ovarian Brenner Tumor

MalaCards organs/tissues related to Malignant Ovarian Brenner Tumor:

39
Ovary, Endothelial, Brain

Publications for Malignant Ovarian Brenner Tumor

Articles related to Malignant Ovarian Brenner Tumor:

id Title Authors Year
1
Malignant ovarian Brenner tumor. A case report evaluated with (18)F-FDG PET/CT. ( 25890890 )
2015
2
The histologic features and histogenesis of malignant ovarian Brenner tumor. ( 3100186 )
1986

Variations for Malignant Ovarian Brenner Tumor

Expression for Malignant Ovarian Brenner Tumor

Search GEO for disease gene expression data for Malignant Ovarian Brenner Tumor.

Pathways for Malignant Ovarian Brenner Tumor

GO Terms for Malignant Ovarian Brenner Tumor

Sources for Malignant Ovarian Brenner Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....